Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy-Reference-Cited by-同舟云学术

Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy

Published:2014-10-30 Issue:18 Volume:124 Page:2824-2833
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Heczey Andras¹,Liu Daofeng¹,Tian Gengwen²,Courtney Amy N.¹,Wei Jie¹,Marinova Ekaterina¹,Gao Xiuhua¹,Guo Linjie¹,Yvon Eric³,Hicks John²,Liu Hao⁴,Dotti Gianpietro²³,Metelitsa Leonid S.¹²³

Affiliation:

1. Texas Children’s Cancer Center, Department of Pediatrics,

2. Department of Pathology and Immunology,

3. Center for Cell and Gene Therapy, and

4. Division of Biostatistics, Dan L. Duncan Cancer Center, Department of Medicine, Baylor College of Medicine, Houston, TX

Abstract

Key Points GD2-specific CAR renders NKT cells cytotoxic against NB cells and results in potent in vivo antitumor activity without graft-versus-host disease. The 4-1BB-containing CAR constructs induce T helper 1–like polarization in NKT cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/124/18/2824/1380698/2824.pdf

Reference51 articles.

1. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology.;Kalos;Immunity,2013

2. Design and development of therapies using chimeric antigen receptor-expressing T cells.;Dotti;Immunol Rev,2014

3. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.;Maher;Nat Biotechnol,2002

4. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.;Imai;Leukemia,2004

5. The basic principles of chimeric antigen receptor design.;Sadelain;Cancer Discov,2013

Cited by 236 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment;Bioactive Materials;2024-12

2. Harnessing Chimeric Antigen Receptor-engineered Invariant Natural Killer T Cells: Therapeutic Strategies for Cancer and the Tumor Microenvironment;Current Pharmaceutical Biotechnology;2024-11

3. Invariant Natural Killer T cells control positively and negatively the development of hepatocellular carcinoma;2024-08-30

4. Current Knowledge and Perspectives of Immunotherapies for Neuroblastoma;Cancers;2024-08-17

5. Traversing the bench to bedside journey for iNKT cell therapies;Frontiers in Immunology;2024-08-07